1. Home
  2. RUM vs VERA Comparison

RUM vs VERA Comparison

Compare RUM & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rumble Inc.

RUM

Rumble Inc.

HOLD

Current Price

$8.10

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

Logo Vera Therapeutics Inc.

VERA

Vera Therapeutics Inc.

HOLD

Current Price

$32.28

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RUM
VERA
Founded
2013
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
3.0B
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
RUM
VERA
Price
$8.10
$32.28
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$81.30
AVG Volume (30 Days)
3.1M
1.9M
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
80.72
N/A
EPS
N/A
N/A
Revenue
$100,622,320.00
N/A
Revenue This Year
$209.98
N/A
Revenue Next Year
$40.99
$472.48
P/E Ratio
N/A
N/A
Revenue Growth
5.38
N/A
52 Week Low
$4.62
$21.15
52 Week High
$10.54
$56.05

Technical Indicators

Market Signals
Indicator
RUM
VERA
Relative Strength Index (RSI) 66.77 44.41
Support Level $5.88 $30.07
Resistance Level $8.68 $32.44
Average True Range (ATR) 0.52 1.66
MACD 0.24 0.15
Stochastic Oscillator 76.87 71.44

Price Performance

Historical Comparison
RUM
VERA

About RUM Rumble Inc.

RUM Group Inc focused is to maximize the power of human imagination through an independent technology ecosystem built on privacy, resilience, and an open alternative to Big Tech. Rumble gives human creativity a voice, a video and media platform built for creators and audiences who value free expression. Quake AI is a cloud and AI-infrastructure business, delivering the compute, data-center capacity, and blockchain infrastructure for the agentic era.

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Share on Social Networks: